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Abstract
Background
HIV infection is an independent risk factor for PAH, but the underlying pathogenesis
remains unclear. ET-1 is a robust vasoconstrictor and key mediator of pulmonary vascular
homeostasis. Higher levels of ET-1 predict disease severity and mortality in other forms of
PAH, and endothelin receptor antagonists are central to treatment, including in HIV-associ-
ated PAH. The direct relationship between ET-1 and PAH in HIV-infected individuals is not
well described.
Methods
Wemeasured ET-1 and estimated pulmonary artery systolic pressure (PASP) with trans-
thoracic echocardiography (TTE) in 106 HIV-infected individuals. Participants with a PASP
 30 mmHg (n = 65) underwent right heart catheterization (RHC) to definitively diagnose
PAH. We conducted multivariable analysis to identify factors associated with PAH.
Results
Among 106 HIV-infected participants, 80% were male, the median age was 52 years and
77% were on antiretroviral therapy. ET-1 was significantly associated with higher values of
PASP [14% per 0.1 pg/mL increase in ET-1, p = 0.05] and PASP 30 mmHg [PR (preva-
lence ratio) = 1.24, p = 0.012] on TTE after multivariable adjustment for PAH risk factors.
Similarly, among the 65 individuals who underwent RHC, ET-1 was significantly associated
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Conclusions
Higher levels of ET-1 are independently associated with HIV-associated PAH as hemody-
namically assessed by RHC. Our findings suggest that excessive ET-1 production in the
setting of HIV infection impairs pulmonary endothelial function and contributes to the devel-
opment of PAH.
Introduction
Pulmonary arterial hypertension (PAH) is a rare but serious clinical complication of HIV
infection. HIV-associated PAH carries an exceptionally poor prognosis (median survival 0.5 to
3.6 years depending on NYHA functional class) and is an independent risk factor for HIV-
related mortality.[1–3] The prevalence of HIV-associated PAH remains approximately 0.5%
even in the highly active antiretroviral therapy (ART) era, a rate that has alarmingly not
changed compared to that of pre-ART cohorts.[4,5] However, this prevalence does not include
asymptomatic individuals—whom we have previously reported to have high pulmonary artery
pressures independent of other risk factors for PAH—and thus may underestimate the actual
burden of HIV-associated PAH.[6]
Despite recent advances in the pathogenesis of HIV-associated PAH, the mechanisms by
which HIV infection causes endothelial dysfunction and subsequent development of PAH
remain poorly defined. The HIV proteins Nef and Tat contribute to key processes in PAH
including vasoconstriction, cellular proliferation, inflammation, and thrombosis.[7,8] Our
group has recently shown that asymmetric dimethylarginine (ADMA), a marker of nitric oxide
mediated endothelial dysfunction that accumulates with chronic inflammation, independently
predicts HIV-associated PAH.[9,10]
Endothelins are potent vasoconstricting peptides that have proliferative and pro-inflamma-
tory effects, with the isoform ET-1 being a well-established mediator of pulmonary vascular
homeostasis.[11] Among other subtypes of PAH, higher levels of endothelin-1 (ET-1) are pre-
dictive of severity and mortality, and endothelin receptor antagonists (ERAs) improve clinical
and hemodynamic parameters, making them a mainstay of PAH therapy.[12–18] Bosentan, a
non-selective ERA, has similarly been shown to improve clinical outcomes in HIV-infected
individuals on ART.[19–21] In HIV infection, the HIV envelope glycoprotein gp120 stimulates
macrophages and pulmonary arterial endothelial cells to secrete ET-1.[22,23] A recently pub-
lished study by Feijoo et al. of 23 HIV-infected patients using Doppler transthoracic echocardi-
ography (TTE) demonstrated that plasma levels of ET-1 were higher among individuals with
elevated pulmonary artery systolic pressure (PASP) than among uninfected controls and
increased with the severity of PASP.[24] While echocardiography is used to screen for PAH,
the gold standard for diagnosis of PAH is hemodynamic assessment by right heart catheteriza-
tion (RHC).[25]
Collectively, these studies support that ET-1 plays a key role in the pathogenesis of HIV-
associated PAH. However, the direct relationship between ET-1 and hemodynamically
assessed mPAP in HIV-infected individuals has not been studied. The purpose of our study
was to evaluate the association between plasma levels of ET-1 and HIV-associated PAH diag-
nosed by right heart catheterization (RHC). We hypothesized that elevated levels of ET-1
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would be associated with higher pulmonary artery pressures, and more specifically, PAH,
among HIV-infected individuals and would provide additional support for ET-1 mediated
endothelial dysfunction as an important mechanism underlying HIV-associated PAH.
Methods
Study Population and Design
We invited HIV-infected participants from the Study of the Consequences of the Protease
Inhibitor Era (SCOPE) cohort to undergo Doppler transthoracic echocardiography (TTE) and
blood draw for plasma levels of ET-1 and HIV markers using study flyers posted in outpatient
clinics. SCOPE is an ongoing, prospective outpatient cohort of greater than 1,500 HIV-infected
patients based at San Francisco General Hospital. Documented HIV infection was the only
inclusion criterion; we did not use HIV-associated disease characteristics, risk factors for PAH,
or symptoms of PAH as selection criteria. There were no exclusion criteria. Non-invasive
screening for PAH by TTE (the current standard of practice) was performed on all subjects.
Each participant with a PASP 30 mmHg was offered an invasive RHC to establish a defini-
tive diagnosis of PAH. All study subjects provided written informed consent. The UCSF Com-
mittee on Human Research approved this study.
Participant Characteristics
Each participant completed a comprehensive assessment of demographics (age, gender, race/
ethnicity), HIV-related factors, and established risk factors for PAH including the use of stimu-
lants (i.e. cocaine and/or amphetamine/methamphetamine use) both intravenously and via
non-parenteral routes. A chart review was also performed to assess duration of HIV infection,
nadir CD4+ count (lowest documented value prior to study entry), and ART regimen.
Blood Measurements
Fasting venous blood was drawn from each subject. Current CD4+ count, HIV RNA level, and
lipid panel were measured at the San Francisco General Hospital clinical laboratory. For
plasma levels of ET-1, blood samples were immediately centrifuged at 4°C and subsequently
stored at -80°C. ET-1 levels were measured using the QuantiGlo ET-1 Chemiluminescent
Immunoassay (R&D Systems, Minneapolis, MN).
Echocardiography
The same experienced sonographer performed all TTEs using a GE Vivid Seven Imaging Sys-
tem (General Electric, Milwaukee, WI). Peak tricuspid regurgitant jet velocity measured by
continuous-wave Doppler was used to estimate the pressure gradient between the right ventri-
cle and right atrium via the modified Bernoulli equation.[26] PASP was subsequently calcu-
lated by adding this pressure gradient to the right atrial pressure, which was estimated by the
respiratory variation in inferior vena cava diameter.[27]
Right Heart Catheterization
All participants with a PASP 30 mmHg on TTE were given the opportunity to undergo
RHC. The same experienced Interventional Cardiologist (JSM) performed all RHCs following
a standard protocol. A 7 French sheath was first inserted into the internal jugular or femoral
vein. Next, a balloon-tipped, flow-directed pulmonary artery catheter (Edwards Biosciences,
Irvine, CA) was advanced to the right atrium. The pressure transducer was then zeroed at the
level of the left atrium. The catheter was ultimately advanced to the pulmonary artery where
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hemodynamic measurements including mPAP, mean pulmonary capillary wedge pressure
(PCWP), cardiac output by Fick’s principle, and pulmonary vascular resistance (PVR) were
recorded. Routine measurement of left ventricular end diastolic pressure was not done.
Definitions and Outcomes
The current accepted definition of pulmonary hypertension is a resting mPAP 25 mmHg by
RHC.[25] PAH (WHO Group 1) is a subgroup of pulmonary hypertension in which the
PCWP is 15 mmHg, the PVR is 3 Wood units, and other etiologies of pulmonary hyper-
tension including lung disease and chronic thromboembolic disease are absent. Thus, subjects
meeting criteria for PAH underwent routine pulmonary function testing, computed tomogra-
phy of the chest, and ventilation-perfusion imaging to rule out chronic obstructive pulmonary
disease, interstitial lung disease, and chronic thromboembolic disease, respectively, to establish
a diagnosis of HIV-associated PAH.
We investigated 4 main outcomes: 1) PASP on TTE evaluated as a continuous variable, 2)
PASP on TTE evaluated as a dichotomous variable 30 mmHg, 3) mPAP on RHC evaluated as
a continuous variable, and 4) mPAP on RHC evaluated as a dichotomous variable 25 mmHg
with PCWP 15 mmHg (i.e. PAH).
Statistical Covariates and Analysis
Candidate covariates of elevated pulmonary arterial pressures included ET-1, demographic
characteristics, and established risk factors for PAH. For the univariable analyses, we first built
generalized linear regression models with log link function to assess the relationship between ET-
1 (independent variable) and both PASP on TTE and mPAP on RHC (dependent variables) and
calculate percentage differences in both variables. Next, we fit Poisson regression models using
PROC GENMOD to estimate prevalence ratios (PR) and examine the association between each
covariate and 1) PASP 30 mmHg, and 2) mPAP 25 mmHg and PCWP 15 mmHg.We
applied the model-robust sandwich variance estimator to all analyses because when Poisson
regression is applied to a binary outcome, the standard error is overestimated, leading to wider
confidence intervals.[28–29] For the multivariable models, we applied a penalized regression
method (LASSO regression) to select candidate covariates associated with continuous outcome
variables, while forcing in demographic covariates.[30] This method allowed for the selection of
relevant covariates and the estimation of their regression coefficients in final models. We fit the
multivariable Poisson regression models with the covariates selected by LASSO regression. Anal-
yses were performed using the SAS system, version 9.3 (SAS Institute, Inc., Cary, NC) and R
package glmnet (version 3.1.2).
Results
Participant Characteristics
Wemeasured levels of ET-1 in 106 HIV-infected participants (Table 1). Overall, the median
(interquartile range [IQR]) age was 52 years (IQR 44–57), 80% were men, 9% had current intra-
venous drug use (IVDU), and 20% were currently using stimulant drugs non-parenterally. The
median duration of HIV infection was 16 years (IQR 10–22), 77% were on ART, the median cur-
rent CD4+ count was 591 cells/μL (IQR 366–757), and 69% had an undetectable viral load.
Relationship between ET-1 and PASP on TTE
The overall median level of ET-1 was 1.78 pg/ml (IQR 1.38–2.18). Among the 19 subjects with
a PASP< 30 mmHg and 87 subjects with a PASP 30 mmHg, the median levels of ET-1 were
Endothelin-1 Predicts HIV-Associated PAH
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1.38 pg/ml (IQR 1.19–1.73) and 1.89 pg/ml (IQR 1.48–2.32), respectively. Elevated levels of
ET-1 predicted higher values of PASP (14% per 0.1 pg/ml increase in ET-1, p = 0.05, Table 2A)
and increased risk of having PASP 30 mmHg (PR = 1.24 per 0.1 pg/ml increase in ET-1,
p = 0.012, Table 2B) in the univariable analysis. These associations remained statistically signif-
icant after multivariable adjustment (PASP: 18%, p = 0.023, Table 2A; PASP 30 mmHg:
PR = 1.27, p = 0.013, Table 2B). Additionally, stimulant IVDU and female gender were inde-
pendently associated with increased PASP (Table 2A), while stimulant IVDU was also inde-
pendently associated with PASP 30 mmHg (Table 2B).
Relationship between ET-1 and PAH on RHC
Of the 87 participants with a PASP 30 mmHg on TTE, 65 (75%) consented to undergo an
elective RHC. This RHC subgroup had a significantly higher percentage of men and current
CD4+ counts but similar nadir CD4+ counts and HIV RNA levels compared to the non-RHC
cohort (Table 1). Among the RHC subgroup, 16 (25%) subjects fulfilled the hemodynamic cri-
teria described above to establish a diagnosis of true PAH (Table 3). Of these 16 individuals
with PAH, 4 (25%) were female and all were on ART and asymptomatic. Among the 47 sub-
jects with a mPAP< 25 mmHg, the median level of ET-1 was 1.81 pg/ml (IQR 1.46–2.20). The
median level of ET-1 was 2.22 pg/ml (IQR 1.79–2.99) among the 16 subjects with PAH. Higher
levels of ET-1 predicted increased values of mPAP (28% per 0.1 pg/ml increase in ET-1,
p = 0.06, Table 4A) and higher risk of PAH (PR = 2.35 per 0.1 pg/ml increase in ET-1,
Table 1. Baseline Characteristics of HIV-Infected Subjects.
Parameter All Subjects (N = 106) RHC (N = 65) Non-RHC (N = 22) p-value
Age (yr) 52 (44–57) 52 (46–57) 48 (42–57) 0.27
Male 85 (80%) 54 (83%) 14 (64%) 0.03
Race 0.61
Caucasian 53 (50%) 33 (51%) 8 (36%)
African American 34 (32%) 20 (31%) 10 (45%)
Latino 11 (10%) 7 (11%) 2 (9%)
Other 8 (8%) 5 (7%) 2 (9%)
Stimulant IVDU (ever) 43 (41%) 33 (51%) 6 (27%) 0.06
Stimulant IVDU (current) 10 (9%) 8 (12%) 2 (9%) 0.68
Stimulant Non-Parenteral Use (ever) 63 (59%) 41 (63%) 11 (50%) 0.28
Stimulant Non-Parenteral Use (current) 21 (20%) 17 (26%) 2 (9%) 0.09
Duration of HIV Infection (yr) 16 (10–22) 17 (12–22) 16 (12–21) 0.87
ART Use (ever) 88 (83%) 59 (91%) 19 (86%) 0.56
ART Use (current) 82 (77%) 55 (85%) 18 (82%) 0.76
ART Duration (yr) 4.5 (1.0–9.4) 5.8 (1.8–9.6) 5.9 (1.4–10.1) 0.80
Current CD4+ (cells/μL) 591 (366–757) 637 (376–768) 430 (231–672) 0.04
Nadir CD4+ (cells/μL) 184 (40–268) 133 (38–250) 172 (43–264) 0.74
HIV RNA (Viral Load) 0.81
<75 (copies/mL) 73 (69%) 49 (75%) 15 (68%)
75–1999 (copies/mL) 15 (14%) 7 (11%) 2 (9%)
2000–9999 (copies/mL) 6 (6%) 2 (3%) 1 (5%)
>10000 (copies/mL) 12 (11%) 7 (11%) 4 (18%)
ART, antiretroviral therapy; IVDU, intravenous drug use; RHC, right heart catheterization.
Data are presented as median (interquartile range) or numbers (percent).
doi:10.1371/journal.pone.0146355.t001
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p = 0.033, Table 4B) in the univariable analysis. These associations remained statistically signif-
icant in the multivariable analysis (mPAP: 34%, p = 0.003, Table 4A; PAH: PR = 2.39,
p = 0.028, Table 4B). Among subjects with PAH, current and nadir CD4+ counts showed little
association with levels of ET-1 (data not shown). Older age was also independently associated
with increased mPAP (Table 4A).
Discussion
The pathogenesis of PAH in the setting of HIV infection remains poorly understood despite
new insights into the mechanistic roles of ADMA and the HIV proteins Nef and Tat.[7–9] A
recent study by Feijoo et al. reported that plasma levels of ET-1 increased as the severity of
HIV-associated PAH assessed non-invasively on TTE progressed.[24] In the present study, we
observed a similar relationship between elevated levels of ET-1 and higher pulmonary artery
pressures estimated by TTE. However, we expand upon these findings by demonstrating that,
among HIV-infected individuals, elevated levels of ET-1 are independently associated with
hemodynamically assessed PAH by invasive RHC (the diagnostic gold standard). This relation-
ship has not been previously described to our knowledge and importantly provides additional
evidence that ET-1 contributes to the pathogenesis of HIV-associated PAH (Fig 1).
Our study and that of Feijoo et al. had several key differences. First, they used a cutoff of
PASP 35 mmHg on TTE to diagnose PAH. While echocardiography is commonly used to
screen for elevated PASP, a formal diagnosis of PAH requires direct hemodynamic assessment
via RHC. In our study, of the 42 individuals who had a PASP 35 mmHg on TTE and
Table 2. Factors Associated with PASP on TTE in HIV-Infected Subjects.
A. PASP
Univariable Multivariable
Parameter % Estimate (95% CI), p-value % Estimate (95% CI), p-value
ET-1 (per 0.1 pg/ml increase) 14% (0%, 31%), p = 0.050 18% (2%, 36%), p = 0.023
Age (per decade) -8% (-16%, 1%), p = 0.090 -8% (-16%, 0%), p = 0.064
Male vs. Female -18% (-33%, -1%), p = 0.037 -18% (-32%, -1%), p = 0.035
African-American vs. Caucasian 3% (-11%, 18%), p = 0.74 -4% (-17%, 10%), p = 0.51
Latino vs. Caucasian 16% (-16%, 62%), p = 0.37 22% (-9%, 64%), p = 0.18
Other vs. Caucasian -8% (-21%, 7%), p = 0.28 -3% (-18%, 15%), p = 0.71
Stimulant IVDU (ever vs. never) 21% (5%, 40%), p = 0.009 16% (0%, 34%), p = 0.046
B. PASP  30 mmHg
Univariable Multivariable
Parameter PR (95% CI), p-value PR (95% CI), p-value
ET-1 (per 0.1 pg/ml increase) 1.24 (1.05, 1.48), p = 0.012 1.27 (1.05, 1.52), p = 0.013
Age (per decade) 1.00 (0.97, 1.04), p = 0.804 1.00 (0.97, 1.04), p = 0.989
Male vs. Female 0.84 (0.73, 0.97), p = 0.016 0.87 (0.73, 1.05), p-0.145
African-American vs. Caucasian 1.18 (0.98, 1.41), p = 0.081 1.13 (0.92, 1.39), p = 0.240
Latino vs. Caucasian 1.06 (0.77, 1.45), p = 0.727 1.08 (0.77, 1.51), p = 0.661
Other vs. Caucasian 1.13 (0.84, 1.53), p = 0.42 1.20 (0.89, 1.61), p = 0.237
Stimulant IVDU (current vs. not current) 1.17 (0.99, 1.38), p<0.001 1.28 (1.09, 1.51), p = 0.002
CI, confidence interval; ET-1, endothelin-1; IVDU, intravenous drug use; PASP, pulmonary artery systolic
pressure; PR, prevalence ratio; TTE, transthoracic echocardiography.
Analysis includes all 106 HIV-infected subjects. PASP is log-transformed; results are back-transformed to
calculate estimated percentage differences in PASP attributable to each covariate.
doi:10.1371/journal.pone.0146355.t002
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Table 3. Hemodynamic Assessment by RHC of HIV-Infected Subjects with PAH.
Participant mPAP (mmHg) PCWP (mmHg) CO (L/min) PVR (WU)
1 32 5 3.7 7.3
2 25 8 3.6 4.7
3 42 9 5.3 6.2
4 27 12 4.0 3.8
5 46 10 3.9 9.2
6 34 10 4.4 5.5
7 48 5 3.5 12.3
8 30 8 6.4 3.4
9 54 8 5.0 9.2
10 26 12 4.0 3.5
11 25 14 3.6 3.1
12 51 6 6.8 6.6
13 29 10 5.0 3.8
14 32 7 3.1 8.1
15 60 7 4.8 11
16 68 8 3.8 15.8
CO, cardiac output (measured by Fick’s principle); mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PCWP, pulmonary
capillary wedge pressure; PVR, pulmonary vascular resistance; RHC, right heart catheterization; WU, Wood units.
doi:10.1371/journal.pone.0146355.t003
Table 4. Factors Associated with mPAP on RHC in HIV-Infected Subjects.
A. mPAP
Univariable Multivariable
Parameter % Estimate (95% CI), p-value % Estimate (95% CI), p-value
ET-1 (per 0.1 pg/ml increase) 28% (-1%, 67%), p = 0.060 34% (11%, 63%), p = 0.003
Age (per decade) -16% (-28%, -2%), p = 0.031 -17% (-29%, -4%), p = 0.015
Male vs. Female 1% (-15%, 19%), p = 0.946 3% (-15%, 26%), p = 0.733
African-American vs. Caucasian -10% (-28%, 13%), p = 0.382 -1% (-18%, 20%), p = 0.918
Latino vs. Caucasian 2% (-33%, 55%), p = 0.926 12% (-25%, 68%), p = 0.567
Other vs. Caucasian -28% (-46%, -5%), p = 0.023 -10% (-26%, 10%), p = 0.326
Stimulant IVDU (ever vs. never) 25% (0%, 56%), p = 0.047 16% (-4%, 40%), p = 0.137
B. PAH (mPAP  25 mmHg)
Univariable Multivariable
Parameter PR (95% CI), p-value PR (95% CI), p-value
ET-1 (per 0.1 pg/ml increase) 2.35 (1.07, 5.13), p = 0.033 2.39 (1.10, 5.20), p = 0.028
Age (per decade) 0.77 (0.49, 1.20), p = 0.246 0.69 (0.41, 1.14), p = 0.145
Male vs. Female 0.88 (0.30, 2.59), p = 0.820 0.96 (0.34, 2.70), p = 0.940
African American vs. Caucasian 0.92 (0.36, 2.35), p = 0.856 1.17 (0.44, 3.11), p = 0.754
Latino/Other vs. Caucasian 0.61 (0.15, 2.43), p = 0.485 1.05 (0.24, 4.56), p = 0.950
CI, confidence interval; ET-1, endothelin-1; IVDU, intravenous drug use; mPAP, mean pulmonary artery
pressure; PAH, pulmonary arterial hypertension; PR, prevalence ratio; RHC, right heart catheterization.
Analysis includes the subgroup of 65 HIV-infected subjects who underwent RHC. mPAP is log-transformed;
results are back-transformed to calculate estimated percentage differences in mPAP attributable to each
covariate.
doi:10.1371/journal.pone.0146355.t004
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underwent RHC, only 15 had true PAH. Using echocardiography alone to identify PAH as was
done in the study by Feijoo et al. would have misclassified 64% of these individuals, highlight-
ing the limitations of echocardiography to establish a diagnosis of PAH. We employed a cutoff
of 30 mmHg to screen subjects for PAH because 1) our group recently found that using the
lower threshold resulted in less missed cases of PAH among HIV-infected individuals, and 2) a
PASP 30 mmHg on TTE has been shown to predict mortality in certain patient populations
who are at risk for PAH.[31,32] Next, Feijoo et al. reported an overall median level of ET-1 of
1.16 pg/ml (IQR 0.86–2.37) among 23 HIV patients with elevated PASP on TTE. In compari-
son, the level of ET-1 among 16 subjects diagnosed with HIV-associated PAH on RHC in our
study was 2.22 pg/ml (IQR 1.79–2.99), which is significantly higher and likely reflects a greater
disease burden. For example, 38% of our PAH cohort had severe PAH as compared to 17% of
their cohort. Finally, Feijoo et al. did not report a statistically significant difference in levels of
ET-1 between HIV-infected patients with and without elevated PASP on TTE. In contrast, we
observed an independent relationship between ET-1 and PASP as both a continuous and
dichotomous variable among our HIV cohort. This difference is likely due to a smaller sample
size (n = 68 vs. n = 106) and thus less power to detect an association in the Feijoo et al. study.
[24]
HIV-associated PAH carries an exceedingly poor survival rate and independently predicts
HIV-specific mortality, rendering it one of the most devastating non-AIDS complications of
HIV infection.[1–3] In fact, the survival rate is worse than those in other forms of PAH accord-
ing to some reports.[1,33] The reported prevalence rate of 0.5% reflects symptomatic patients
carrying a clinical diagnosis of HIV-associated PAH but fails to capture the asymptomatic
PAH population.[4,5] In our study, 15% of an asymptomatic HIV cohort was found to have
subclinical PAH. Thus, earlier recognition of HIV-associated PAH including intervention
before development of symptoms may play a role in improvement in clinical outcomes. Our
study showed that higher levels of ET-1 are independently associated with HIV-associated
Fig 1. Proposed Mechanism by which ET-1 Contributes to the Development of HIV-Associated PAH.
ET-1, endothelin-1; PAH, pulmonary arterial hypertension.
doi:10.1371/journal.pone.0146355.g001
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PAH in an asymptomatic and previously undiagnosed cohort. The levels of ET-1 in our HIV-
associated PAH cohort [median 2.22 pg/ml (IQR 1.79–2.99)] are substantially higher than
those observed in healthy individuals; for example, Feijoo et al. reported a median ET-1 level of
0.71 pg/ml (IQR 0.54–0.94) among 11 controls.[22,34,35] Prior studies of other forms of PAH
demonstrated that elevated levels of ET-1 are correlated with worse hemodynamic features and
mortality; the ET-1 levels in those series were higher than in our study, reflecting more cases of
severe PAH.[13,15–17] Taken together, these findings suggest that ET-1 may be considered as
both a screening biomarker and prognostic tool for HIV-associated PAH, though additional
longitudinal studies with outcome data would be required for validation.
As a principal mediator of pulmonary vascular homeostasis, ET-1 has long been a chief
therapeutic target in PAH in the form of ERAs. Two distinct receptor subtypes mediate the bio-
activity of ET-1: 1) ET-A receptors on vascular smooth muscle cells, and 2) ET-B receptors on
both endothelial and vascular smooth muscle cells. Stimulation of the vascular smooth muscle
cell ET-A and ET-B receptors causes vasoconstriction whereas binding of ET-1 to endothelial
ET-B receptors triggers the release of the potent vasodilators NO and prostacyclin.[11] There-
fore, selective blockade of ET-A receptors may theoretically lead to greater overall vasodilation
compared to non-selectively blocking both ET-A and ET-B receptors. Bosentan, a non-selec-
tive ERA, is the only ERA that has been studied in clinical trials focused on HIV-associated
PAH. It has been shown to improve both clinical and hemodynamic parameters in patients
with advanced disease on ART.[19–21] The ET-A selective ERA Ambrisentan was extensively
studied in 3 sequential trials of PAH (overall N = 393, 11 of whom had HIV-associated PAH)
and was found to similarly improve pulmonary hemodynamics and delay clinical progression.
[36–38] Head-to-head studies of non-selective versus selective blockade of ET-1 receptors are
needed to establish the first-line ERA in HIV-associated PAH. Future investigation is also
required to determine if ERAs delay the development of PAH or the onset of symptoms in
asymptomatic PAH in this population.
Though ET-1 was the only candidate covariate to demonstrate an independent association
with all outcomes including PAH, we detected significant associations for both female gender
and stimulant IVDU with certain measures of pulmonary pressure. PAH registries report an
overall gender influence with a female to male ratio of nearly 4:1 for all etiologies of PAH.
However, HIV-associated PAH specifically exhibits a male predominance given that the over-
whelming majority of HIV-infected individuals are men.[39,40] We observed that female gen-
der was significantly associated with PASP on TTE, but notably not with PAH by RHC;
overall, our findings are consistent with the registry data. Lastly, the significant associations we
found between stimulant IVDU and various measures of pulmonary pressure were expected
given that it is a known risk factor for PAH.
The present study has key limitations. First, the study’s cross-sectional design prevents the
determination of causality. Though a mechanistic link exists between HIV infection, ET-1, and
PAH (HIV gp120 stimulates macrophages and pulmonary arterial endothelial cells to secrete
ET-1), a larger longitudinal study showing that elevated levels of ET-1 predict the development
of PAH in HIV-infected patients and are higher than those in uninfected controls would be
required to establish a causal relationship and support ET-1 as a potential biomarker of HIV-
associated PAH, respectively.[22,23] Nonetheless, our observations are consistent with the
results of the recent study by Feijoo et al. and previous observations in cross-sectional studies
of other subtypes of PAH, and thus reinforces that ET-1 is one of the mechanisms by which
HIV-associated PAH develops.[13,15–17,24] Second, we did not directly measure pulmonary
endothelial ET-1 levels. However, ET-1 expression is highest in the pulmonary vasculature and
PAH patients have higher circulating plasma levels of ET-1 as well as increased ET-1 levels
exiting the lung than entering the lung.[11,41] These observations suggest that the elevated
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plasma levels of ET-1 we observed in the HIV-associated PAH cohort likely reflects impaired
pulmonary endothelium. Third, the impact of ET-1 compared to other predictors on HIV-
associated PAH is unclear. Serial measurement of Nef, Tat, ADMA, and ET-1 levels over time
in an HIV population would help shed light on the relative contributions of each of these
mechanistic factors. Lastly, the inherent inaccuracy of TTE in measuring pulmonary artery
pressure is a fundamental limitation. Doppler echocardiography, when compared to the gold
standard of RHC, inaccurately estimates PASP in approximately 50% of the cases in general
PAH cohorts (defined as> ±10 mmHg difference between TTE and RHC).[42,43] Similarly,
our group recently reported that among HIV-infected patients, TTE inaccurately estimated
PASP in 20% of the cases and that 29% of diagnoses of HIV-associated PAH were missed using
a screening threshold of PASP 30 mmHg on TTE.[31] Collectively, these findings suggest
that we may have failed to detect cases of PAH in this study among individuals with a
PASP< 30 mmHg on TTE and highlights the need for a more sensitive tool than echocardiog-
raphy to screen for HIV-associated PAH.
In summary, elevated plasma levels of ET-1 are independently associated with PAH diag-
nosed by RHC in the setting of HIV infection. Our study is the first to our knowledge to link
ET-1 to hemodynamically assessed HIV-associated PAH, thus extending upon the existing
echocardiographic literature. This finding supports our hypothesis that ET-1 disrupts pulmo-
nary endothelial function and plays a mechanistic role in the development of HIV-associated
PAH. Future studies in HIV-infected patients are required to determine sensitive ET-1 thresh-
olds for earlier recognition of PAH and to assess if higher levels of ET-1 predict functional or
clinical outcomes. Additionally, the possibility of using ET-1 to predict success of endothelin
receptor antagonism in this population warrants further investigation. HIV-infected individu-
als (Pulido T NEJM 2013). Larger investigations targeted at use of ET-1 levels and lowering
ET-1 with ERA in HIV-PAH will be needed to establish the efficacy and safety of the different
ERA in HIV. In addition, the benefit of lowering ET-1 among asymptomatic HIV-infected
individuals with the purpose of delaying development of PAH or delaying symptom onset
remains unknown.
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